The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2023 | PIONEER trial update: avapritinib for indolent systemic mastocytosis
Prithviraj Bose, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the placebo-controlled Phase II PIONEER trial (NCT03731260), which is investigating avapritinib in patients with indolent systemic mastocytosis (SM). The primary endpoint of the trial was met – a significantly greater mean reduction in total symptom score (TSS) was observed in the avapritinib arm versus the placebo arm. Dr Bose shares results from other endpoints, and comments on the reduction in SM biomarker burden observed with avapritinib. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
